Anderson GL, et al. - In this single-center, retrospective cohort study of patients who received adjunctive glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention, researchers compared in-hospital outcomes before and after an institution-wide switch to high-dose bolus (HDB) tirofiban with shortened infusion from short-duration eptifibatide. They mainly focused on the occurrence of major and minor bleeding and cardiovascular events (death, myocardial infarction, coronary artery bypass grafting, ischemic stroke, and target vessel revascularization). They did not observe any increase in-hospital bleeding or cardiovascular events in relation to the use of HDB tirofiban with shortened infusion vs short-duration eptifibatide.